AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a higher bid. The private-equity firm plans to bid against rival Advent ...

The co-founder of bankrupt genetic analysis company 23andMe won an auction for the firm’s assets, agreeing, along with a ...

This was the stock's second consecutive day of gains.

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed ...